Bioject Medical Technologies, Inc. (BJCT) - 500 Beiträge pro Seite
eröffnet am 11.12.06 20:36:25 von
neuester Beitrag 14.01.07 15:14:18 von
neuester Beitrag 14.01.07 15:14:18 von
Beiträge: 8
ID: 1.099.633
ID: 1.099.633
Aufrufe heute: 0
Gesamt: 847
Gesamt: 847
Aktive User: 0
ISIN: US09059T2069 · WKN: 874950
0,0001
USD
0,00 %
0,0000 USD
Letzter Kurs 05.04.16 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,3000 | +70,98 | |
| 1,7850 | +42,80 | |
| 1,0700 | +31,13 | |
| 1,6500 | +29,92 | |
| 1,7500 | +27,27 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 23,390 | -16,34 | |
| 0,7500 | -16,67 | |
| 0,5305 | -17,51 | |
| 3,5000 | -26,24 | |
| 11,500 | -29,23 |
Feedback
Profile:Bioject Medical Technologies, Inc. engages in the development, manufacture, and distribution of needle-free drug delivery systems to the pharmaceutical and biotechnology industries. Its products include Biojector 2000, which enables healthcare professionals to deliver measured variable doses of medication through the skin, either intramuscularly or subcutaneously, without a needle; and drug reconstitution system that allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. In addition, the company offers Vitajet, which is designed for subcutaneous self-injection of insulin in the home. Further, the company is also developing Iject prefilled device for delivery of its drug to treat a specific condition. The company has licensing and/or development agreements with Ares Serono, PATH, and Merial for the development of needle-free injection systems. Bioject Medical was founded in 1985 and is headquartered in Tualatin, Oregon.
http://www.bioject.com/
http://www.bioject.com/
habe mir ein paar gestern geschnappt
NIH Utilizes Biojector(R) 2000 in Avian Influenza Study
Thursday January 4, 7:00 am ET
PORTLAND, Ore., Jan. 4 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT - News), a leading developer of needle-free drug delivery systems, today announced that the National Institutes of Health ("NIH") is utilizing the Biojector® 2000 ("B2000") in its first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection. The vaccine was administered to the first volunteer a few weeks ago at the NIH clinical center in Bethesda, MD.
The study will enroll 45 volunteers between the ages of 18 and 60. Fifteen will receive placebo injections and 30 will receive three injections of the investigational vaccine over two months and will be followed for one year. Volunteers will not be exposed to influenza virus.
"We're pleased to be working with the NIH and for it choosing our needle free injection technology for such an important clinical study and the advancement in medicine. It is a clinical advantage to be able to offer this vaccine with a needle free delivery system thus making it safer for patients and clinicians. We have found that it may potentially provide a therapeutic benefit from improved immunogenicity as we have seen with other vaccines," said Richard R. Stout M.D., Vice President Clinical Affairs at Bioject. "The NIH is also using the B2000 needle free system with its DNA HIV vaccines that are currently in clinical trials throughout the world."
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information on Bioject, visit www.bioject.com.
--------------------------------------------------------------------------------
Source: Bioject Medical Technologies Inc.
Thursday January 4, 7:00 am ET
PORTLAND, Ore., Jan. 4 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT - News), a leading developer of needle-free drug delivery systems, today announced that the National Institutes of Health ("NIH") is utilizing the Biojector® 2000 ("B2000") in its first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection. The vaccine was administered to the first volunteer a few weeks ago at the NIH clinical center in Bethesda, MD.
The study will enroll 45 volunteers between the ages of 18 and 60. Fifteen will receive placebo injections and 30 will receive three injections of the investigational vaccine over two months and will be followed for one year. Volunteers will not be exposed to influenza virus.
"We're pleased to be working with the NIH and for it choosing our needle free injection technology for such an important clinical study and the advancement in medicine. It is a clinical advantage to be able to offer this vaccine with a needle free delivery system thus making it safer for patients and clinicians. We have found that it may potentially provide a therapeutic benefit from improved immunogenicity as we have seen with other vaccines," said Richard R. Stout M.D., Vice President Clinical Affairs at Bioject. "The NIH is also using the B2000 needle free system with its DNA HIV vaccines that are currently in clinical trials throughout the world."
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information on Bioject, visit www.bioject.com.
--------------------------------------------------------------------------------
Source: Bioject Medical Technologies Inc.
Trading Spotlight
Das sieht doch gut aus
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,93 | |
| +0,48 | |
| -1,37 | |
| +0,56 | |
| +2,29 | |
| +0,23 | |
| -1,85 | |
| +0,62 | |
| -0,19 | |
| +0,89 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 210 | ||
| 106 | ||
| 85 | ||
| 75 | ||
| 42 | ||
| 41 | ||
| 38 | ||
| 34 | ||
| 33 | ||
| 30 |
